Tradestie Institutional Equity Comparison Engine

AVDL vs HROW โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AVDL Overall Edge

AVDL Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, AVDL trades at 28.8x Forward P/E with 2.5% operating margin (+54.9% YoY revenue) versus HROW at 62.9x Forward P/E and -2.0% operating margin (+38.6% YoY). In options structure, AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against HROW sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner AVDL
AVDL 28.8x vs HROW 62.9x Fwd P/E
Growth & Margin Winner AVDL
Op Margin 2.5% vs -2.0% ยท YoY +54.9% vs +38.6%
Momentum & Technical Winner AVDL
1Y +138.1% vs -23.2% ยท 52W Pos 89% vs 16%
Options & Structure Winner AVDL
UNCLASSIFIED (<1st %ile IV) vs BREAKDOWN (8th %ile IV)
AVDL NASDAQ
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
1M Return +0.65%
1Y Return +138.06%
Forward P/E 28.8x
Unified AI Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
HROW NASDAQ
Harrow, Inc. Common Stock
Pharmaceutical Preparations
$30.41
-5.35% 1D
Market Cap $1.2B
1M Return +8.03%
1Y Return -23.21%
Forward P/E 62.9x
Unified AI Score
32.2 / 100 SELL
Tech 20.0 Fund 43.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AVDL +138.06% HROW -23.21% Spread: +29.2 pp (HROW Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AVDL TTM Op. Margin: 2.5% HROW TTM Op. Margin: -2.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs HROW. Trailing 12-month operating profitability (AVDL 2.5% vs HROW -2.0%) and valuation multiples (AVDL 28.8x vs HROW 62.9x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AVDL (10) vs HROW (0)
Institutional Metric AVDL HROW Criterion Row Winner
Market Capitalization Scale $2.1B $1.2B Larger Scale AVDL
Trailing P/E Ratio Valuation 16.8x 62.9x Lower Multiple AVDL
Forward P/E Ratio Valuation 28.8x 62.9x Lower Multiple AVDL
Revenue Growth (YoY) Growth +54.9% +38.6% Higher Growth AVDL
Operating Margin (TTM) Profitability 2.5% -2.0% Higher Margin AVDL
Net Profit Margin Profitability -0.1% -9.4% Higher Margin AVDL
Return on Equity (ROE) Capital Efficiency -0.3% -75.5% Higher ROE AVDL
52-Week Range Position Momentum 89% ($6โ€“$24) 16% ($26โ€“$55) Stronger Trend AVDL
Beta / 30D Volatility Risk Regime 0.14ฮฒ ยท 2% Vol 1.08ฮฒ ยท 72% Vol Lower Realized Risk AVDL
Unified Institutional Score Composite Signal 62.9 / 100 (BUY) 32.2 / 100 (SELL) Higher Composite AVDL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AVDL vs HROW Buy Guide
AVDL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live AVDL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
HROW BREAKDOWN
89d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live HROW Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AVDL nor HROW registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.